Company Overview
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology. The company offers regenerative dermal and soft tissue fillers; 3D-bioprinted regenerative breast implants; Collage, a combinant human Collagen type I solution; VergenixSTR, a soft tissue matrix for the treatment of tendinopathy; and VergenixFG, a wound care product for the treatment of deep surgical incisions and deep wounds. It also provides rhcollagen-based commercial bioink for regenerative medicine applications, such as Collink.3D 50L, a bioink in powder form; Collink.3D 90, an rhCollagen-based bioink solution for use in various 3D bioprinting applications; and Collink.3D 50, an rhCollagen-based bioink product. The company has collaboration agreements with AbbVie; STEMCELL; the Advanced Regenerative Manufacturing Institute; Stratasys; and RegenMed Development Organization. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.
Why Investors Should Care
Net profit has compounded at 10.7% per year over the last five years.
Revenue has grown at a 99.4% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $2.37M (+360.4% YoY); net profit $-11.49M.
- Trailing 12 Months Year-on-year growth — revenue -96.4%.
- 5-Year Trend Long-term compounding — revenue CAGR 99.4%, profit CAGR 10.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 99.41% |
| 1 Year: | -96.40% |
Compounded Profit Growth
| 5 Years: | 10.71% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +31.62% |
| 6 Months: | -43.17% |
| 3 Months: | -3.24% |
| 1 Month: | +5.60% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)55.74 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 99.4% over 5 years.
- Profit CAGR of 10.7% over 5 years.
CONS
- Trading 88.6% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CLGN CollPlant Biotechnologies Ltd. PHARMA | 3.58 | -0.34 | $6.77M | 0.00% | -141.54% | - | 99.41% | 10.71% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 2.06M | 179.00K | 77.00K | 60.00K | 73.00K |
| Cost of Revenue | - | 188.00K | 186.00K | 269.00K | 192.00K | 316.00K |
| Gross Profit | - | 1.87M | -7.00K | -192.00K | -132.00K | -243.00K |
| Operating Expenses | - | 3.52M | 3.17M | 3.31M | 3.02M | 2.87M |
| Operating Income | - | -1.65M | -3.18M | -3.51M | -3.15M | -3.12M |
| EBITDA | - | -1.40M | -2.95M | -3.28M | -2.93M | -2.90M |
| Interest Expense | - | - | - | - | - | - |
| Pretax Income | - | -1.45M | -3.35M | -3.48M | -3.21M | -3.10M |
| Tax Provision | - | - | - | - | - | - |
| Net Income | - | -1.45M | -3.35M | -3.48M | -3.21M | -3.10M |
| Diluted EPS | - | -0.13 | -0.28 | -0.27 | - | -0.23 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 299.00K | 10.96M | 515.00K | 2.37M |
| Cost of Revenue | 400.00K | 1.99M | 1.62M | 835.00K |
| Gross Profit | -101.00K | 8.97M | -1.11M | 1.54M |
| Operating Expenses | 17.00M | 16.48M | 16.14M | 13.02M |
| Operating Income | -17.10M | -7.51M | -17.25M | -11.48M |
| EBITDA | -16.02M | -6.41M | -16.21M | -10.57M |
| Interest Expense | - | - | - | - |
| Pretax Income | -16.93M | -7.02M | -16.61M | -11.49M |
| Tax Provision | - | - | - | - |
| Net Income | -16.93M | -7.02M | -16.61M | -11.49M |
| Diluted EPS | -1.53 | -0.62 | -1.45 | -0.94 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 37.77M | 34.13M | 18.71M | 10.79M |
| Current Assets | - | 31.66M | 28.02M | 13.18M | 6.75M |
| Cash & Equivalents | - | 29.65M | 26.67M | 11.91M | 5.59M |
| Inventory | - | 1.43M | 714.00K | 440.00K | 573.00K |
| Receivables | - | 9.00K | 0 | 150.00K | 1.00K |
| Total Liabilities | - | 5.49M | 5.79M | 5.25M | 4.70M |
| Current Liabilities | - | 3.10M | 3.25M | 2.97M | 2.67M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 2.91M | 3.16M | 3.08M | 2.85M |
| Total Equity | - | 32.28M | 28.34M | 13.46M | 6.08M |
| Shares Outstanding | - | 11.19M | 11.47M | 11.47M | 12.82M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -13.70M | -2.76M | -14.09M | -9.42M |
| Investing Cash Flow | - | 28.92M | -1.16M | -539.00K | -27.00K |
| Financing Cash Flow | - | 1.87M | 1.11M | 9.00K | 3.10M |
| Capital Expenditure | - | -1.32M | -954.00K | -483.00K | -28.00K |
| Free Cash Flow | - | -15.01M | -3.72M | -14.58M | -9.45M |
| Net Change in Cash | - | 17.10M | -2.81M | -14.62M | -6.34M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | -33.8% | 81.8% | -215.5% | 64.8% |
| Operating Margin % | -5,718.1% | -68.5% | -3,349.7% | -484.3% |
| Net Margin % | -5,660.5% | -64.0% | -3,225.0% | -484.6% |
| ROE % | -52.4% | -24.8% | -123.3% | -188.9% |
| ROCE % | -49.3% | -24.3% | -109.6% | -141.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Pinnacle Associates, Ltd. | 0.39% | 73.17K | $333.64K |
| 2 | Villere St. Denis J. & Co. LLC | 0.32% | 60.64K | $276.52K |
| 3 | Brown Advisory Inc. | 0.06% | 10.47K | $47.76K |
| 4 | Renaissance Technologies, LLC | 0.03% | 6.15K | $28.04K |
| 5 | Pathstone Holdings, LLC | 0.03% | 5.70K | $25.99K |
| 6 | Citadel Advisors Llc | 0.03% | 5.37K | $24.49K |
| 7 | Legacy Wealth Managment, LLC/ID | 0.01% | 2.32K | $10.57K |
| 8 | Waters Parkerson & Co., LLC | 0.01% | 1.32K | $6.04K |
| 9 | Xtx Topco Ltd | 0.01% | 1.31K | $5.96K |
| 10 | FNY Investment Advisers, LLC | - | 525 | $2.39K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CLGN
CollPlant (NASDAQ: CLGN) gives CFO 510,372 RSUs with 5-year vesting - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxOUHdDMGE4bHhQU3BHY2JXRjQ1eEZWMjdaTFJ0TU5WaGxpRHJXaXVCbDVoOXJ2ZEcyVVRvb2FPMXB0a21sTW1TNkN1OU9VbDFLUGFFS3RheTJ4cVNLVXZ5c2stV01mQnZWYkRQQ2hTNVJ4WjRTck1mci1lanphN1FvMVp4UzZ4OVpPSmwwWX…
Why CollPlant Biotechnologies (CLGN) Stock Is Up Today - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxOV2lvT3hSUVRNMmRodlVyZkdaUllPMVJmQ201YnNFOXZwbG5rbExDUkVnQUlHdVNtOUFsYVRjYWM3b1dFSFVSVlFQM3dSU0t1TG1Cb3JsSmJWc29QUjltMGh0MzRaYnI4ZkhXeUlpQXFiVTNsdHdhanU2ZGo3WFFPQzJmNnJvV0kzUW5mWT…
CLGN Looks 14.7% Overvalued on GF Value™ - gurufocus.com
<a href="https://news.google.com/rss/articles/CBMiggFBVV95cUxOTWU1Qm9qQ3Q5ZlYzX05QNi1xMWs5dy04S0JwcU1xbmRqNHpnUzdJT0xHV2Z3amk3UmZrbWtJSnFHWDhCcHl0TUtJdEJGemJGazVHRmg4N2x1Y3hwT09STURGUWJibkJuNWU3TG04ZUxwS1ZuaVJZNUVnWUJONHh2ZzNB?oc=5" target=…
A physicist who helped create light-based computing joins CollPlant's board - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxOVmxuZTFQZHVYYUZtX2ZIa2dFUGZSUTMyMDZhWWRhMUNsV0hyU0RrZVBQVm9SSFYzSDdxb2hjdm1NQ25WdjNDZXFpUkpPNzVXWmlUUy1rVXVCVXRxdUZ2cDdIekNGZEZaZEJ4U0JGV0lWVHJENDhkaHZURU1xR3Bna0M4X2dIU0pjMkNZc0…
When Will CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Turn A Profit? - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxPd2xYSElOcVJzNkdrYVdERHpmX3NzNkMyODNuQ1dOV0VCUUlyX1k4NkVlN0lYbFhRR0ptd1ZLQndvMXBjVEZ3bWstUE9VRGZfNURSdE5zcUk1dUhJVTNpNFRLVjFSNC1IN1YzRDhsbUNraHctWnZvNUppcmNwdDZXYzR0SlM1TThSeGIxQT…
COLLPLANT ANNOUNCES REVERSE SHARE SPLIT >CLGN - Moomoo
<a href="https://news.google.com/rss/articles/CBMijwFBVV95cUxPc24wSG1lNldQeFdkZ0Z2Q3BocEd0YlczVEwyNkcyZk5MeGloalRYaGJWLTdKRVplaHdnYkZQUGpOVjN1Tk1XekFJeXVsV3pTSnVlRkxVN0Q0SU41QnV5OUVvQmJ3OEVxdTFTUXZNNFM2XzN1bldlZlNTemZneWcxZGJXMXRvRDRZTWkzbX…
CLGN — Frequently Asked Questions
What is the current share price of CollPlant Biotechnologies Ltd. (CLGN)?
As of 2026-09-19 21:16 PDT, CollPlant Biotechnologies Ltd. (CLGN) trades at $3.58 on NasdaqCM. Its 52-week range is $1.97 to $31.40.
What is the market capitalisation of CLGN?
CollPlant Biotechnologies Ltd. (CLGN) has a market capitalisation of $6.77M on NasdaqCM.
What is the P/E ratio of CLGN?
CLGN trades at a trailing price-to-earnings (P/E) ratio of -0.34. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.01.
Is CLGN a good stock to buy?
This page provides a data-driven analysis of CollPlant Biotechnologies Ltd. (CLGN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.